×
S&P 500   3,845.54 (-1.40%)
DOW   31,153.04 (-0.91%)
QQQ   285.64 (-2.33%)
AAPL   138.86 (-1.98%)
MSFT   258.76 (-2.31%)
META   163.35 (-3.62%)
GOOGL   2,247.01 (-3.01%)
AMZN   108.09 (-4.53%)
TSLA   703.14 (-4.30%)
NVDA   160.85 (-4.65%)
NIO   22.31 (-2.79%)
BABA   117.22 (-1.27%)
AMD   80.94 (-6.06%)
MU   58.52 (-0.44%)
CGC   3.61 (-4.75%)
T   20.71 (-0.34%)
GE   65.77 (-1.41%)
F   11.93 (-0.91%)
DIS   97.25 (+0.66%)
AMC   13.64 (-3.47%)
PFE   50.52 (-2.62%)
PYPL   72.52 (-4.50%)
NFLX   181.85 (-3.85%)
S&P 500   3,845.54 (-1.40%)
DOW   31,153.04 (-0.91%)
QQQ   285.64 (-2.33%)
AAPL   138.86 (-1.98%)
MSFT   258.76 (-2.31%)
META   163.35 (-3.62%)
GOOGL   2,247.01 (-3.01%)
AMZN   108.09 (-4.53%)
TSLA   703.14 (-4.30%)
NVDA   160.85 (-4.65%)
NIO   22.31 (-2.79%)
BABA   117.22 (-1.27%)
AMD   80.94 (-6.06%)
MU   58.52 (-0.44%)
CGC   3.61 (-4.75%)
T   20.71 (-0.34%)
GE   65.77 (-1.41%)
F   11.93 (-0.91%)
DIS   97.25 (+0.66%)
AMC   13.64 (-3.47%)
PFE   50.52 (-2.62%)
PYPL   72.52 (-4.50%)
NFLX   181.85 (-3.85%)
S&P 500   3,845.54 (-1.40%)
DOW   31,153.04 (-0.91%)
QQQ   285.64 (-2.33%)
AAPL   138.86 (-1.98%)
MSFT   258.76 (-2.31%)
META   163.35 (-3.62%)
GOOGL   2,247.01 (-3.01%)
AMZN   108.09 (-4.53%)
TSLA   703.14 (-4.30%)
NVDA   160.85 (-4.65%)
NIO   22.31 (-2.79%)
BABA   117.22 (-1.27%)
AMD   80.94 (-6.06%)
MU   58.52 (-0.44%)
CGC   3.61 (-4.75%)
T   20.71 (-0.34%)
GE   65.77 (-1.41%)
F   11.93 (-0.91%)
DIS   97.25 (+0.66%)
AMC   13.64 (-3.47%)
PFE   50.52 (-2.62%)
PYPL   72.52 (-4.50%)
NFLX   181.85 (-3.85%)
S&P 500   3,845.54 (-1.40%)
DOW   31,153.04 (-0.91%)
QQQ   285.64 (-2.33%)
AAPL   138.86 (-1.98%)
MSFT   258.76 (-2.31%)
META   163.35 (-3.62%)
GOOGL   2,247.01 (-3.01%)
AMZN   108.09 (-4.53%)
TSLA   703.14 (-4.30%)
NVDA   160.85 (-4.65%)
NIO   22.31 (-2.79%)
BABA   117.22 (-1.27%)
AMD   80.94 (-6.06%)
MU   58.52 (-0.44%)
CGC   3.61 (-4.75%)
T   20.71 (-0.34%)
GE   65.77 (-1.41%)
F   11.93 (-0.91%)
DIS   97.25 (+0.66%)
AMC   13.64 (-3.47%)
PFE   50.52 (-2.62%)
PYPL   72.52 (-4.50%)
NFLX   181.85 (-3.85%)
NASDAQ:MRNS

Marinus Pharmaceuticals Stock Forecast, Price & News

$4.91
-0.20 (-3.91%)
(As of 06/28/2022 01:28 PM ET)
Add
Compare
Today's Range
$4.90
$5.14
50-Day Range
$4.09
$7.71
52-Week Range
$3.97
$19.40
Volume
2,292 shs
Average Volume
574,119 shs
Market Capitalization
$182.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.14
30 days | 90 days | 365 days | Advanced Chart

Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Stock Forecast (MarketRank)

Overall MarketRank

1.99 out of 5 stars

Medical Sector

601st out of 1,436 stocks

Pharmaceutical Preparations Industry

276th out of 687 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock News Headlines

Revisiting Marinus Pharmaceuticals
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
113
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/28/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$32.14
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+554.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-98.78 million
Net Margins
-328.21%
Pretax Margin
-328.21%

Debt

Sales & Book Value

Annual Sales
$15.35 million
Book Value
$1.34 per share

Miscellaneous

Free Float
35,625,000
Market Cap
$182.36 million
Optionable
Optionable
Beta
1.51














Marinus Pharmaceuticals Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Marinus Pharmaceuticals stock.
View analyst ratings for Marinus Pharmaceuticals
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price forecast for 2022?

6 Wall Street research analysts have issued 12-month target prices for Marinus Pharmaceuticals' shares. Their MRNS stock forecasts range from $22.00 to $50.00. On average, they predict Marinus Pharmaceuticals' share price to reach $32.14 in the next twelve months. This suggests a possible upside of 554.6% from the stock's current price.
View analysts' price targets for Marinus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Marinus Pharmaceuticals' stock performed in 2022?

Marinus Pharmaceuticals' stock was trading at $11.88 on January 1st, 2022. Since then, MRNS shares have decreased by 58.7% and is now trading at $4.91.
View the best growth stocks for 2022 here
.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,420,000 shares, an increase of 30.1% from the May 31st total of 1,860,000 shares. Based on an average daily trading volume, of 347,400 shares, the short-interest ratio is currently 7.0 days. Currently, 7.5% of the shares of the company are short sold.
View Marinus Pharmaceuticals' Short Interest
.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Marinus Pharmaceuticals
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.35. The biopharmaceutical company had revenue of $14.19 million for the quarter, compared to analysts' expectations of $2.19 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 145.46% and a negative net margin of 328.21%.
View Marinus Pharmaceuticals' earnings history
.

When did Marinus Pharmaceuticals' stock split? How did Marinus Pharmaceuticals' stock split work?

Marinus Pharmaceuticals shares reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of Marinus Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Dr. Scott N. Braunstein M.D., CEO, Pres & Director (Age 59, Pay $869.03k)
  • Mr. Steven E. Pfanstiel C.M.A., M.B.A., CFO & Treasurer (Age 49, Pay $553.91k)
  • Dr. Joseph Hulihan M.D., Chief Medical Officer (Age 66, Pay $621.91k)
  • Ms. Sasha Damouni Ellis, VP of Corp. Affairs & Investor Relations
  • Ms. Martha E. Manning, VP, Gen. Counsel & Sec. (Age 67)
  • Mr. Thomas J. Lyons, Sr. VP of Corp., Bus. Devel. & Commercial Planning
  • Ms. Lisa Lejuwaan, VP of Sales
  • Ms. Sonya Weigle, VP of HR
  • Dr. Kimberly A. McCormick Pharm.D., PharmD, Sr. VP and Head of Regulatory Affairs & Quality Assurance
  • Dr. Alex Aimetti Ph.D., Sr. VP of Scientific Affairs

What other stocks do shareholders of Marinus Pharmaceuticals own?

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Suvretta Capital Management LLC (7.47%), BlackRock Inc. (7.09%), Vanguard Group Inc. (4.58%), Bleichroeder LP (3.57%), State Street Corp (1.78%) and Granite Point Capital Management L.P. (1.28%). Company insiders that own Marinus Pharmaceuticals stock include Edward F Smith and Scott Braunstein.
View institutional ownership trends for Marinus Pharmaceuticals
.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP, State Street Corp, Northern Trust Corp, UBS Group AG, Bank of Montreal Can, Simplex Trading LLC, and Citigroup Inc..
View insider buying and selling activity for Marinus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was purchased by a variety of institutional investors in the last quarter, including Bleichroeder LP, Suvretta Capital Management LLC, Granite Point Capital Management L.P., Group One Trading L.P., Renaissance Technologies LLC, Virtu Financial LLC, Cutler Group LP, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Marinus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $4.91.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $182.36 million and generates $15.35 million in revenue each year. The biopharmaceutical company earns $-98.78 million in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

Marinus Pharmaceuticals employs 113 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for Marinus Pharmaceuticals is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at [email protected], or via fax at 203-315-0565.

This page (NASDAQ:MRNS) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.